KÖSTEK, O. Et Al. 2019. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?. Cancer chemotherapy and pharmacology , vol.83 , 115-122.

KÖSTEK, O., HACıOĞLU, M., Sakin, A., DEMIR, T., SARı, M., OZKUL, O., ... ARAZ, M.(2019). Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?. Cancer chemotherapy and pharmacology , vol.83, 115-122.

KÖSTEK, O Et Al. "Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?," Cancer chemotherapy and pharmacology , vol.83, 115-122, 2019

KÖSTEK, O Et Al. "Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?." Cancer chemotherapy and pharmacology , vol.83, pp.115-122, 2019

KÖSTEK, O. Et Al. (2019) . "Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?." Cancer chemotherapy and pharmacology , vol.83, pp.115-122.

@article{article, author={O KÖSTEK Et Al. }, title={Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?}, journal={Cancer chemotherapy and pharmacology}, year=2019, pages={115-122} }